Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC
Category: #health  By Nikita Chaurasia  Date: 2020-03-30
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Esperion presents pooled analyses of NEXLETOL & NEXLIZET at ACC.20/WCC

Esperion Therapeutics, a US-based public pharmaceutical company, reportedly unveiled that two pooled data analyses from its 4 Phase 3 clinical studies of NEXLETOL and outcomes from Phase 2 trial of NEXLIZET were showcased during the ACC.20/WCC.

In a poster session that was showcased by Harold E Bays, FOMA, MD, FTOS, FACE, FTOS, FNLA, FACC., it was highlighted that in Phase 2 trial, NEXLIZET lowered LDL-C significantly by a 40% mean as compared placebo, lowered hsCRP by 25% in comparison to the baseline, and further did not worsen glycemic control.

Along with the first poster, an additional poster session was conducted by Eric S. G. Stroes, MD., PhD. This poster signified that inside the pooled Phase 3 trials, NEXLETOL substantially decreased hsCRP in patients suffering from hypercholesterolemia irrespective of the intensity or presence of background statin treatment.

The third and final poster session was conducted by Maciej Banach, Ph.D., FESC, FAHA, MD. In the session it was highlighted that in Phase 3, NEXLETOL facilitated significant additional lowering of LDL-C while also significantly lowering other lipid endpoints, irrespective of background ezetimibe presence. Most notably, NEXLETOL’s safety profile was similar without or with background ezetimibe treatment.

Tim Mayleben, President and the Chief Executive Officer of Esperion stated that the company is thrilled with the final outcomes of Phase 2 trials that signifies NEXLIZET gained a 40 percent LDL-C lowering, a substantial 25 percent decrease in hsCRP and did not exacerbate glycemic control in patients suffering from Type 2 diabetes. The pooled analyses from Phase 3 LDL-C decreasing development program shows that NEXLETOL can be safely integrated with multiple LDL-C medicines, crucial to aid more patients to achieve their LDL-C objectives.

Mayleben further added that these analyses assure the safety and efficacy of the company’s medicines for millions of patients wanting to decrease their bad cholesterol levels.

 

Source credit: https://www.esperion.com/investors-media/press-releases/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Spotify to allow access to all creators in its video podcast platform

Spotify to allow access to all creators in its video podcast platform

By Nikita Chaurasia

Audio streaming giant Spotify has announced the launch of its video podcast feature, which will be provided by its self-publishing podcast division, Anchor. According to sources, the feature will initially be offered on a rolling basis where interes...

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...